EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Scar - Pipeline Review, H2 2015

  • ID: 3448671
  • Report
  • September 2015
  • 112 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • 3M Drug Delivery Systems
  • Altacor Limited
  • Biokine Therapeutics Ltd.
  • Derma Sciences, Inc.
  • Fibrocell Science, Inc.
  • LegoChem Biosciences, Inc
  • MORE
Scar - Pipeline Review, H2 2015

Summary

The report ‘Scar - Pipeline Review, H2 2015’, provides an overview of the Scar’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Scar, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Scar and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Scar
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Scar and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Scar products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Scar pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Scar
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Scar pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3M Drug Delivery Systems
  • Altacor Limited
  • Biokine Therapeutics Ltd.
  • Derma Sciences, Inc.
  • Fibrocell Science, Inc.
  • LegoChem Biosciences, Inc
  • MORE
List of Tables

List of Figures

Introduction

REPORT COVERAGE

Scar Overview

Therapeutics Development

Pipeline Products for Scar - Overview

Pipeline Products for Scar - Comparative Analysis

Scar - Therapeutics under Development by Companies

Scar - Therapeutics under Investigation by Universities/Institutes

Scar - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Scar - Products under Development by Companies

Scar - Products under Investigation by Universities/Institutes

Scar - Companies Involved in Therapeutics Development

3M Drug Delivery Systems

AlbireoPharma

Altacor Limited

Beech Tree Labs, Inc.

Biokine Therapeutics Ltd.

Clanotech AB

Critical Outcome Technologies Inc.

Derma Sciences, Inc.

Easton Pharmaceuticals Inc.

EyeGene, Inc.

Fibrocell Science, Inc.

FirstString Research, Inc.

Isarna Therapeutics GmbH

Juventas Therapeutics, Inc.

LegoChem Biosciences, Inc

Moerae Matrix, Inc.

Pergamum AB

RXi Pharmaceuticals Corporation

Symic Biomedical, Inc.

VBS Pharmaceuticals

Scar - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

A-3914 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

A-5425 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

aclerastide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

azficel-T - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BKT-170 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BTL-slo - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CLT-28643 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CM-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

decorin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug to Agonize Beta 2 Receptor for Wound Scars - Drug Profile

Product Description

Mechanism of Action

R&D Progress

EGS-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

EP-003 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Granexin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ISTH-0036 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

JVS-100 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LCB-030110 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MMI-0100 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

nefopam hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OLX-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Polysaccharide for Wounds and Scars - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PXL-01 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Recombinant Protein for Scar - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RXI-109 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

S-34240 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Wounds and Scars - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Activate SOX-9 for Scar - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tranilast - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Scar - Recent Pipeline Updates

Scar - Dormant Projects

Scar - Discontinued Products

Scar - Product Development Milestones

Featured News & Press Releases

Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology

Mar 23, 2015: RXi Pharmaceuticals Reports Positive Advancements in its Dermatology Programs at the Occasion of the 73rd Annual Meeting of the American Academy of Dermatology

Dec 17, 2014: RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

Sep 29, 2014: RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum

Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders

Feb 03, 2014: RXi Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference

Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period

Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision

Jul 15, 2013: FirstString Research, Inc. Announces the Achievement of Primary Endpoints in Three Phase 2 Clinical Trials of Granexin™ Gel for the Treatment of Chronic Wounds and Scar Reduction

Jul 12, 2013: RXi Pharmaceuticals Announces Positive Data in Second Phase 1 Multi-Dose Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Scar, H2 2015

Number of Products under Development for Scar - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2015

Scar - Pipeline by 3M Drug Delivery Systems, H2 2015

Scar - Pipeline by AlbireoPharma, H2 2015

Scar - Pipeline by Altacor Limited, H2 2015

Scar - Pipeline by Beech Tree Labs, Inc., H2 2015

Scar - Pipeline by Biokine Therapeutics Ltd., H2 2015

Scar - Pipeline by Clanotech AB, H2 2015

Scar - Pipeline by Critical Outcome Technologies Inc., H2 2015

Scar - Pipeline by Derma Sciences, Inc., H2 2015

Scar - Pipeline by Easton Pharmaceuticals Inc., H2 2015

Scar - Pipeline by EyeGene, Inc., H2 2015

Scar - Pipeline by Fibrocell Science, Inc., H2 2015

Scar - Pipeline by FirstString Research, Inc., H2 2015

Scar - Pipeline by Isarna Therapeutics GmbH, H2 2015

Scar - Pipeline by Juventas Therapeutics, Inc., H2 2015

Scar - Pipeline by LegoChem Biosciences, Inc, H2 2015

Scar - Pipeline by Moerae Matrix, Inc., H2 2015

Scar - Pipeline by Pergamum AB, H2 2015

Scar - Pipeline by RXi Pharmaceuticals Corporation, H2 2015

Scar - Pipeline by Symic Biomedical, Inc., H2 2015

Scar - Pipeline by VBS Pharmaceuticals, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Scar Therapeutics - Recent Pipeline Updates, H2 2015

Scar - Dormant Projects, H2 2015

Scar - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Scar, H2 2015

Number of Products under Development for Scar - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015
Note: Product cover images may vary from those shown
3 of 4
3M Drug Delivery Systems
AlbireoPharma
Altacor Limited
Beech Tree Labs, Inc.
Biokine Therapeutics Ltd.
Clanotech AB
Critical Outcome Technologies Inc.
Derma Sciences, Inc.
Easton Pharmaceuticals Inc.
EyeGene, Inc.
Fibrocell Science, Inc.
FirstString Research, Inc.
Isarna Therapeutics GmbH
Juventas Therapeutics, Inc.
LegoChem Biosciences, Inc
Moerae Matrix, Inc.
Pergamum AB
RXi Pharmaceuticals Corporation
Symic Biomedical, Inc.
VBS Pharmaceuticals
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll